Xencor to Host First Quarter 2021 Financial Results Webcast and Conference Call on May 5, 2021 Read more about Xencor to Host First Quarter 2021 Financial Results Webcast and Conference Call on May 5, 2021
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021 Read more about Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021
Xencor to Present Preclinical Data from Four Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2021 Read more about Xencor to Present Preclinical Data from Four Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2021
Xencor to Present at the Barclays Global Healthcare Conference Read more about Xencor to Present at the Barclays Global Healthcare Conference
Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics Read more about Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics
Xencor Reports Fourth Quarter and Full Year 2020 Financial Results Read more about Xencor Reports Fourth Quarter and Full Year 2020 Financial Results
Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021 Read more about Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021
Xencor to Present at Upcoming Investor Conferences Read more about Xencor to Present at Upcoming Investor Conferences
Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer Read more about Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer
Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer Read more about Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer
